Gyre Therapeutics (NASDAQ:GYRE) Trading Up 4.7% - Should You Buy?

Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report)'s stock price rose 4.7% during trading on Tuesday . The company traded as high as $8.17 and last traded at $8.08. Approximately 50,206 shares were traded during mid-day trading, a decline of 45% from the average daily volume of 91,134 shares. The stock had previously closed at $7.72.

Wall Street Analysts Forecast Growth

Separately, Noble Financial initiated coverage on Gyre Therapeutics in a research report on Tuesday, March 11th. They set an "outperform" rating on the stock.

Gyre Therapeutics Price Performance

The company's 50-day moving average is $9.81 and its 200-day moving average is $11.41. The firm has a market capitalization of $831.27 million, a price-to-earnings ratio of 177.60 and a beta of 2.03.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last posted its quarterly earnings results on Monday, March 17th. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.03). Gyre Therapeutics had a negative net margin of 84.57% and a negative return on equity of 118.43%. The business had revenue of $27.87 million during the quarter, compared to analysts' expectations of $23.50 million.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in GYRE. Geode Capital Management LLC increased its position in shares of Gyre Therapeutics by 16.9% in the 3rd quarter. Geode Capital Management LLC now owns 303,647 shares of the company's stock worth $3,808,000 after purchasing an additional 43,840 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Gyre Therapeutics by 0.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 114,566 shares of the company's stock valued at $1,386,000 after buying an additional 918 shares in the last quarter. State Street Corp lifted its holdings in Gyre Therapeutics by 8.8% during the 3rd quarter. State Street Corp now owns 104,490 shares of the company's stock worth $1,310,000 after buying an additional 8,412 shares during the last quarter. Northern Trust Corp grew its position in shares of Gyre Therapeutics by 9.1% in the 4th quarter. Northern Trust Corp now owns 103,382 shares of the company's stock worth $1,251,000 after acquiring an additional 8,624 shares in the last quarter. Finally, SBI Securities Co. Ltd. acquired a new stake in shares of Gyre Therapeutics during the 4th quarter valued at approximately $1,225,000. 23.99% of the stock is owned by hedge funds and other institutional investors.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.